Who Paid My Doc
Hajra Awwab
Providence, RI Medical Doctor
NPI 1073969424 CMS profile 7232549
593 Eddy Street, Rhode Island Hospital-Graduate Medical Education, Providence, RI 02903
General payments
$48,049
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Hajra Awwab of Providence, RI is reported in the CMS Open Payments database as having received $48,049 across 205 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $6,631 | 51 | |
| 2024 | General | $5,824 | 42 | |
| 2023 | General | $19,181 | 78 | |
| 2022 | General | $16,343 | 30 | |
| 2021 | General | $39 | 3 | |
| 2019 | General | $32 | 1 |
Beside peers
- Hajra Awwab
- Rhode Island median
- Middle half of Rhode Island
- National median
In program year 2025, general payments to Hajra Awwab were reported at $6,631. Among 3,274 Rhode Island profiles paid that year, the median was $167 and the middle half received between $59 and $598.
Show as a table
| Year | Hajra Awwab | Rhode Island median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $32 | $158 | $48–$592 | $163 |
| 2020 | $0 | $114 | $36–$385 | $114 |
| 2021 | $39 | $126 | $38–$462 | $132 |
| 2022 | $16,343 | $143 | $46–$520 | $149 |
| 2023 | $19,181 | $149 | $51–$549 | $160 |
| 2024 | $5,824 | $169 | $65–$580 | $164 |
| 2025 | $6,631 | $167 | $59–$598 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
176
Drug cost
$53,468
Branded share of claims
22.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 40 | $51,284 | |
| Amiodarone Hcl | Generic | 22 | $779 | |
| Metoprolol Succinate | Generic | 46 | $759 | |
| Pantoprazole Sodium | Generic | 25 | $257 | |
| Metoprolol Tartrate | Generic | 32 | $255 | |
| Sucralfate | Generic | 11 | $134 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 47 billing codesPaid by Medicare
$36,377
Medicare patients
222
Services billed
440
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Atrial fibrillation | 64% | |
| Arthritis | 45% | |
| Ischemic heart disease | 44% | |
| Chronic kidney disease | 39% | |
| Diabetes | 35% | |
| Heart failure | 32% | |
| COPD | 22% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
205 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.